{"disease":{"id":"malignant-melanoma-with-braf-v600e-mutation","name":"Malignant Melanoma with BRAF V600E Mutation","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"dabrafenib","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafinlar","generic_name":"dabrafenib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase B-raf","drug_class":"Kinase Inhibitor","quality_score":68,"revenue":"1675","mechanism":"Tafinlar blocks the activity of a mutated protein called BRAF that is involved in cancer cell growth."},{"drug_id":"vemurafenib","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zelboraf","generic_name":"vemurafenib","company_name":"Hoffmann La Roche","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase B-raf","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":"100","mechanism":"Zelboraf blocks the activity of the B-raf protein, which is involved in cell growth and division."},{"drug_id":"cobicistat","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tybost","generic_name":"COBICISTAT","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Tybost works by blocking the enzyme Cytochrome P450 3A, which is responsible for breaking down many other medications."},{"drug_id":"trametinib","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"zelboraf","indication_name":"Malignant Melanoma with BRAF V600E Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zelboraf","company_name":"Hoffmann-La Roche","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase, Ferrochelatase, mitochondrial, Dual specificity mitogen-activated protein kinase kinase 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}